FDA Has No Questions on GRAS Status of Enzymotec Krill Oil

February 6, 2008

1 Min Read
Supply Side Supplement Journal logo in a gray background | Supply Side Supplement Journal

MIGDAL HAEMEQ, Israel—Enzymotec is expanding its krill oil business into other market segments, after the company received a “no questions” response from the U.S. FDA regarding the GRAS (generally recognized as safe) status of its krill lecithin.

"Our krill lecithin is the only one which gained the U.S. FDA confirmation for its GRAS status, while other products have only been self-affirmed" said Ariel Katz, Ph.D., CEO, Enzymotec. "We had very good feedback from customers regarding the product quality and service provided; GRAS is yet another important step in our effort to become a major player in the krill oil market and in functional foods in general," concluded Katz.

Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.

You May Also Like